(VIANEWS) – NEOEN (NEOEN.PA), AKER SOLUTIONS (AKSO.OL), MULTICONSULT (MULTI.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NEOEN (NEOEN.PA)
48.5% sales growth and 7.39% return on equity
Neoen S.A., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. The company operates through Solar Power, Wind Power, Storage, Farm-Down, Development and Investments, and Eliminations segments. It operates in Argentina, Australia, Canada, Ecuador, the United States, Finland, France, Ireland, Italy, Jamaica, Mexico, Mozambique, Portugal, El Salvador, Sweden, and Zambia. Neoen S.A. was incorporated in 2008 and is headquartered in Paris, France. Neoen S.A. operates as a subsidiary of Impala SAS.
Earnings Per Share
As for profitability, NEOEN has a trailing twelve months EPS of €1.14.
PE Ratio
NEOEN has a trailing twelve months price to earnings ratio of 23. Meaning, the purchaser of the share is investing €23 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.39%.
Moving Average
NEOEN’s value is higher than its 50-day moving average of €26.02 and below its 200-day moving average of €28.24.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.6%, now sitting on 556.1M for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 17, 2023, the estimated forward annual dividend rate is 0.13 and the estimated forward annual dividend yield is 0.47%.
More news about NEOEN.
2. AKER SOLUTIONS (AKSO.OL)
16.8% sales growth and 17.09% return on equity
Aker Solutions ASA provides solutions, products, systems, and services to the oil and gas industry worldwide. It offers field planning, feasibility, and concept studies; specialist engineering, project management, and procurement services; floater designs, offshore wind, as well as engages in design, delivery, and construction of deep-water risers, oil, and gas production, and receiving and processing facilities. In addition, the company provides offshore fish farming, carbon capture, utilization and storage, hydrogen, and offshore wind solutions. Further, the company designs and constructs jackets for construction services and offers electrification services; and designs and constructs offshore oil and gas production facilities and onshore receiving and processing facilities. Additionally, the company provides subsea production, compression, pump, power distribution, and processing systems, and subsea lifecycle services. Furthermore, the company offers maintenance, modifications, decommissioning, asset integrity management, hook-up, and completion solutions. Aker Solutions ASA was founded in 1841 and is headquartered in Fornebu, Norway.
Earnings Per Share
As for profitability, AKER SOLUTIONS has a trailing twelve months EPS of kr3.41.
PE Ratio
AKER SOLUTIONS has a trailing twelve months price to earnings ratio of 12.6. Meaning, the purchaser of the share is investing kr12.6 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.09%.
Yearly Top and Bottom Value
AKER SOLUTIONS’s stock is valued at kr42.98 at 01:20 EST, way below its 52-week high of kr50.00 and way above its 52-week low of kr33.14.
Volume
Today’s last reported volume for AKER SOLUTIONS is 408142 which is 37.42% below its average volume of 652249.
Sales Growth
AKER SOLUTIONS’s sales growth for the next quarter is 16.8%.
More news about AKER SOLUTIONS.
3. MULTICONSULT (MULTI.OL)
10% sales growth and 29.75% return on equity
Multiconsult ASA provides engineering design, consultancy, and architecture services in Norway and internationally. The company offers multidisciplinary consultancy, design, planning, project supervision and management, geotechnical site survey, verification and control, analysis and due diligence, construction management, geological investigations, environmental services and HSE, river basin management, hydrometry, and hydrological field work services. It serves buildings and properties, cities and society, industry, oil and gas, renewable energy, rail and transportation, and water and environment sectors. Multiconsult ASA was founded in 1908 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MULTICONSULT has a trailing twelve months EPS of kr10.22.
PE Ratio
MULTICONSULT has a trailing twelve months price to earnings ratio of 11.59. Meaning, the purchaser of the share is investing kr11.59 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.75%.
More news about MULTICONSULT.
4. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 21.6. Meaning, the purchaser of the share is investing kr21.6 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr21.60 at 01:20 EST, way below its 52-week high of kr25.10 and way above its 52-week low of kr11.70.
Revenue Growth
Year-on-year quarterly revenue growth grew by 54.7%, now sitting on 410.31M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA’s EBITDA is 43.61.
More news about VISTIN PHARMA.
